Clinical trial · Interventional
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07667868CI-TRIAL-00123238not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Multiple Myeloma (RRMM) | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BP2202 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BP2202
- interventionNames
- Biological: BP2202
Primary outcomes (2)
- measure
- Incidence of dose-limiting toxicities (DLTs; Part A)
- timeFrame
- Up to 6 weeks
- description
- Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to BP2202
- measure
- Incidence of adverse events (AEs; Parts A and B)
- timeFrame
- Up to approximately 2 years
- description
- Number of participants who experienced AEs, adverse events of special interest (AESIs), or serious adverse events (SAEs)
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of Multiple Myeloma with relapsed or refractory disease. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 * Adequate organ function. * Have measurable disease Exclusion Criteria: * Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma. * Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.
References
Publications (0)
Data not yet available
No reference posted for this study.